title: Nivolumab provides favorable results in patients with advanced melanoma.
authors.forename: Surabhi
authors.initials: S
authors.lastname: Dangi-Garimella
mesh_terms: D061605:Administration, Intravenous; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects* / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D060890:B7-H1 Antigen / Q000187:drug effects / Q000276:immunology; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology; D000077594:Nivolumab; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; D000077594:Nivolumab